Generic drug makerLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field. in IndiaLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field.. FDA records under 5 spellings of its name, each linked to the record.
As of Nov 15, 2026, FDA's public records list Natco Pharma and its 1 subsidiaries with 69 drug applications, 2 drug recalls and 2 warning letters. The most recent is a warning letter dated Sep 25, 2025: Warning letter: Drugs.
Drug approvals, 510(k) clearances, recalls and letters, 2017 to 2026 to date, Natco Pharma and its 1 subsidiaries
A hatched bar is a year that is not over, so its count covers only part of the year.
| Sep 25, 2025 | Warning letter: DrugsCDER | Warning letters |
| Apr 8, 2024 | Warning letter: Cleaning validation, Out-of-specification, Quality unitCDER | Warning letters |
| Mar 27, 2024 | Lansoprazole Delayed-Release Capsules USP, 15 mg, Acid reducer 24 Hour, Treats Frequent Heartburn, 14 capsules per bottle, Manufactured by: Class II · CGMP Deviations | Drug recalls |
| Feb 1, 2024 | Lansoprazole Delayed-Release Capsules USP, 15 mg, 14-count bottle, Manufactured by: Natco Pharma Limited Kothur- 509 228, India, DistributedClass II · CGMP Deviations: Inadequate induction sealing on bottles, capsules were observed with bubbles on band seal, capsules wit | Drug recalls |
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata. How this page is built